To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Feature Video
Dr Noopur Raje opens this program with a brief discussion on the basics of multiple myeloma. She describes what the disease is, highlights key risk factors, and explains how she helps educate her patients on their diagnosis. Cynthia Harrington discusses her role as a nurse practitioner when working with multiple myeloma patients and why a team-based approach between healthcare providers and the patient is important.
Beth Fand Incollingo
The annual Los Angeles event was launched 11 years ago in honor of Romano’s Everybody Loves Raymond costar, Peter Boyle, who died of the rare blood cancer multiple myeloma in 2006.
Katie Kosko
Patients with multiple myeloma who are eligible for stem cell transplantation should still be considered for high-dose therapy (HDT) even in the novel agent era, according to the authors of a study recently published in the Journal of the American Medical Association Oncology.
Kristie L. Kahl
An abnormal protein found in the blood – called monoclonal gammopathy of undetermined significance (MGUS) – may lead to multiple myeloma progression, even after 30 years of disease stability, according to study results published in the New England Journal of Medicine.
James H. Essell, M.D.
These advancements are changing the way many cancers are being treated.
Brielle Urciuoli
The success of CAR- (chimeric antigen receptor) T cell therapy is causing landmark change in the way that patients with multiple myeloma are being treated, but more research needs to be done to better understand the role that these agents will play.
Joshua Richter, M.D.
A new patient-reported outcomes tool is helping to shift the way end-of-life and depression-related conversations are occurring between patients with multiple myeloma and their health care teams.
Brielle Urciuoli
The Food and Drug Administration (FDA) granted priority review to the combination use of Darzalex (daratumumab), Velcade (bortezomib), melphalan and prednisone for the treatment of newly diagnosed patients with multiple myeloma who are not eligible for autologous stem cell transplant (ACST).
Jason M. Broderick
The Food and Drug Administration (FDA) approved a supplemental new drug application that adds overall survival (OS) data from the phase 3 ENDEAVOR trial to the label for Kyprolis (carfilzomib) to treat patients with relapsed or refractory multiple myeloma.
Kristie L. Kahl
Over the past few years, the Food and Drug Administration (FDA) has approved a variety of triplet combinations for the treatment of patients with multiple myeloma. However, little is known which regimens have the best economic impact, without sacrificing clinical outcomes that is. 
Kristie L. Kahl
The oldest cases of multiple myeloma and breast cancer date back to ancient Egyptian mummies.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable